Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
GEHC
HoldUnloved QualityGE HealthCare Technologies Inc. · Healthcare · United States · $32.4B · Avg Vol: $226M/d
COMPANY DESCRIPTION
GE HealthCare Technologies Inc. is a global medical technology, pharmaceutical diagnostics, and digital solutions innovator, providing a comprehensive portfolio including medical imaging, ultrasound, patient care solutions, and biopharmaceutical manufacturing technologies. The company's competitive moat is founded on its vast installed base, strong brand reputation, deep R&D capabilities, and critical role in improving patient outcomes worldwide. GE HealthCare is a market leader across multiple healthcare segments, leveraging its extensive global reach and technological expertise.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.3B | 19.6B | 19.7B | 20.6B | 4.0% | 21.3B | 21.7B | 22.7B | 5.0% |
| EPS | 4.63 | 3.05 | 4.37 | 4.56 | -0.5% | 4.34 | 4.90 | 5.37 | 8.6% |
| Shares | 454.0M | 455.3M | 457.0M | 455.7M | +0.4% | 451.7M | — | — | — |
| Debt | 8.6B | 9.9B | 9.4B | 10.5B | 6.6% | 10.5B | — | — | — |
| Equity | 9.4B | 7.1B | 8.4B | 10.4B | 3.5% | — | — | — | — |
| Op CF | 2.1B | 2.1B | 2.0B | 2.0B | -2.0% | 2.1B | — | — | — |
| Inv CF | -398.0M | -558.0M | -914.0M | -1.0B | — | — | — | — | — |
| Fin CF | -822.0M | -478.0M | -573.0M | 617.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GEHC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GEHC | GE HealthCare Technologies Inc.(you) | $32.4B | 63 | Hold |
| EW | Edwards Lifesciences Corporation | $52.0B | 64 | Hold |
| STE | STERIS plc | $22.8B | 76 | Buy |
| DXCM | DexCom, Inc. | $34.3B | 83 | Strong Buy |
| BSX | Boston Scientific Corporation | $67.9B | 48 | Hold |
| BIO | Bio-Rad Laboratories, Inc. | $10.4B | 70 | Buy |
| ZBH | Zimmer Biomet Holdings, Inc. | $19.2B | 83 | Strong Buy |
| PEN | Penumbra, Inc. | $12.7B | 51 | Hold |
| SYK | Stryker Corporation | $126.8B | 57 | Hold |
| ABT | Abbott Laboratories | $194.6B | 61 | Hold |
Peer medians: ROE -30.8% · P/E 27.1x · Gross margin 58.3%